



## Accelerate your MiFID II readiness

---

Stratevolve's MiFID II Fast Track Diagnostic is a rapid assessment of the implications and opportunities for investment banks and brokers, resulting from the changing rules around research and inducements.

**Get reassurance about compliance with MiFID II and identify business opportunities resulting from market disruption**



# Why is it important?

MiFID II will be written into national law by July 2017, with full compliance required by 3 January 2018.

Most firms on both the buy-side and sell-side understand that MiFID II is substantially changing the market and competitive landscape and are appreciating the significance of the potential commercial implications. MiFID II will produce clear winners and losers as European research revenues fall by 50% or approximately £1.5bn.

With an increasing number of buy-side firms choosing to pay for research out of their P&L, pressure on sell-side firms to deliver quality research at a pre-agreed price is significant. Sell-side firms need to rapidly assess what they need to do to be MiFID II compliant, and capitalise on the market disruption to strengthen their relative position.

## MiFID II Fast Track Diagnostic

Stratevolve has developed a fast, efficient and cost effective methodology for sell-side firms to assess their readiness and response to MiFID II. Developed on the back of over 3 years of research and hundreds of conversations with both buy-side and sell-side firms, the MiFID II Fast Track Diagnostic is designed to give clear guidance on compliance issues and identify business opportunities.

## What does it involve?

The MiFID II Fast Track Diagnostic involves Stratevolve senior consultants engaging with your firm's management team and compliance in a series of facilitated discussions and structured one-to-one meetings to understand the scope of the research function, research products and services, and commercial arrangements.

The Stratevolve team will focus on identifying the MiFID II compliance issues specific to your firm and assess the impact of these changes on your business.



## What do you get from the Diagnostic?

1. High level plan with specific activities to ensure compliance ahead of January 2018
2. Identification of business opportunities created through MiFID II market disruption
3. High level estimate of the business impact – downside / upside – on your business

## What are the benefits for sell-side firms?

1. Accelerated expert diagnostic – typically completed within 2 weeks
2. Reassurance that all research compliance issues have been identified and implications considered
3. Potential to drive real business opportunity and value from market disruption
4. Informed and evidence based approach conducted by leading experts on MiFID II
5. Implementable plan to ensure compliance and take advantage of business opportunities.



Contact **Glenn Poulter** to discuss how Stratevolve's MiFID II Fast Track Diagnostic can accelerate your understanding of the implications of MiFID II as it relates to research and inducements.

t: 07770 496996 e: [glenn.poulter@stratevolve.com](mailto:glenn.poulter@stratevolve.com)